Can-Fite BioPharma Announces $15 Million Public Offering

Can-Fite BioPharma ( (CANF) ) has shared an update.

On July 28, 2025, Can-Fite BioPharma Ltd. announced a public offering expected to raise up to $15 million, with $5 million upfront and an additional $10 million possible from short-term warrants. The offering, involving 8,333,333 American Depositary Shares and warrants, is priced at $0.60 per ADS and is expected to close on July 29, 2025. The proceeds will fund research, clinical trials, and general corporate purposes, potentially impacting the company’s operational capabilities and market positioning.

The most recent analyst rating on (CANF) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.

Spark’s Take on CANF Stock

According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.

Can-Fite BioPharma’s overall stock score reflects significant financial challenges and a bearish technical outlook. The company’s negative profitability, declining revenues, and reliance on external financing are major concerns. Technical indicators suggest caution, while valuation metrics indicate ongoing losses, affecting investor confidence.

To see Spark’s full report on CANF stock, click here.

More about Can-Fite BioPharma

Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company focused on developing proprietary small molecule drugs for treating cancer and inflammatory diseases. The company targets multi-billion dollar markets with its lead drug candidates, including Piclidenoson for psoriasis and Namodenoson for hepatocellular carcinoma, MASH, and pancreatic cancer. Namodenoson has received Orphan Drug Designation in the U.S. and Europe and Fast Track Designation by the FDA.

Average Trading Volume: 111,875

Technical Sentiment Signal: Sell

Current Market Cap: $14.3M

Find detailed analytics on CANF stock on TipRanks’ Stock Analysis page.